Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Ghent
With
Jessa Hospital
University Hospital, Antwerp
Algemeen Ziekenhuis Maria Middelares
GZA Ziekenhuizen Campus Sint-Augustinus
AZ Sint-Jan AV
AZ Nikolaas
AZ Sint-Lucas Gent
AZ Sint-Lucas Brugge
General Hospital Groeninge
OLV van Lourdes Hospital Waregem
AZ Damiaan
AZ Delta
ASZ Aalst
Belgian Red Cross
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically proven advanced melanoma.
Anti-PD-1 monotherapy of advanced (unresectable or metastatic) melanoma (prescribed within its approved indication as per usual practice according to RIZIV/INAMI regulations) in the first-line setting.
No prior systemic therapy for advanced melanoma.
Have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.
At least 18 years of age.
You may not be if
Prior treatment with any drug specifically targeting T-cell co-stimulation or immune checkpoints (e.g., antibodies targeting PD-(L)1 or CTLA-4, chimeric antigen receptor T (CAR-T) cell therapy).
Metastasis-directed therapy (surgery or radiotherapy) with definitive intent (local therapy to address symptomatic sites of disease is permitted).
Previous systemic treatment for advanced melanoma.
Active central nervous system (CNS) metastases (previously treated brain metastases are permitted if stable) or carcinomatous meningitis.
Diagnosis of any other malignancy within 5 years prior to study inclusion, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the breast or of the cervix, low-risk prostate cancer on surveillance without any plans for treatment intervention, or prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease and symptoms.
Clareo Health | BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs
